Monoclonal antibody therapy uses monoclonal antibodies, which have varied therapeutic uses because a monoclonal antibody can be created to bind specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective, to induce a specific cell signal, to cause the immune system to attack specific cells, or to deliver a drug to a specific cell type.
Facts
Connections
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundationhttps://en.wikipedia.org/wiki/Monoclonal_antibody_therapy, lead sectionQuote, https://en.wikipedia.org/wiki/Monoclonal_antibody_therapy, lead section
Monoclonal antibodies (mAbs) have varied therapeutic uses.
2. Wikipedia: Monoclonal Antibody Therapy
Wikipediahistory section, FDA approval sentenceQuote, history section, FDA approval sentence
The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986.
Frequently Asked Questions
What can monoclonal antibody therapy target?
Almost any extracellular target, such as cell surface proteins and cytokines.
Almost any extracellular target, because a monoclonal antibody can be created to bind specifically to it, including cell surface proteins and cytokines. The antibodies can render their target ineffective, induce a specific cell signal, cause the immune system to attack specific cells, or deliver a drug to a specific cell type.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.